
Xtant Medical Holdings Inc anticipates 2026 revenues and gross margins will be adversely impacted by the non-repeat of $18.7M in 2025 license revenue and the loss of $20.3M from divested Coflex/CoFix products and international hardware business.
Bullish
Xtant Medical Holdings Inc achieved 14% revenue growth and net income for 2025, driven by orthobiologics sales and new product introductions, while improving cash flow from operations.
Bearish
Xtant Medical Holdings Inc faces adverse impacts on 2026 revenues and gross margins from lost license and divested product revenue, along with a material weakness in internal controls over inventory valuation.